Mergeworthrx — SPAC Merger (December 2014)
26 slides from Mergeworthrx's SPAC merger presentation, Dec 1, 2014
Slide 1: Investor Presentation November 2014: MergeWorthRx Business Combination with AeroCare Holdings
I NVESTOR P RESENTATION N OVEMBER 2014 M ERGE W ORTH R X C ORP . B USINESS C OMBINATION WITH A ERO C ARE H OLDINGS , I NC .
Slide 2: Disclaimer
2 Disclaimer ▪ The sole purpose of the presentation is to assist persons in deciding whether they wish to proceed with a further review of the proposed transaction discussed herein and is not intended to be all - inclusive or to contain all the information that a person may desire in considering the
Slide 3: Transaction Overview
3 Transaction Overview Transaction ▪ MergeWorthRx Corp. (NASDAQ: MWRX) to merge with AeroCare Holdings, Inc . (“AeroCare” or the “Company”) in an all stock transaction » Post closing, combined company expected to trade on NASDAQ ▪ Pro forma enterprise value of approximately $212mm and equity value o
Slide 4: AeroCare Investment Highlights
4 AeroCare Investment Highlights ▪ Compelling valuation and transaction structure x 5.9x 2014E Pro Forma Adjusted EBITDA (1) on a fully - diluted basis x Full achievement of earnout targets implies a fully - diluted valuation of 3.4x 2017E Pro Forma Adjusted EBITDA x All stock transaction x MergeWor
Slide 5: AeroCare Overview
5 ▪ AeroCare is one of the fastest organic and total growth Respiratory Therapy (RT) / Durable Medical Equipment (DME) companies among leading sector participants ▪ Founded in late 2000 by Steve Griggs, a long - time healthcare home respiratory and medical equipment executive ▪ Ferrer Freeman (“FFC”
Slide 6: AeroCare Opportunity
6 ▪ Industry Evolution: Medicare payment reform has forced the industry to embrace a distribution / logistics focus over service ▪ Visible Reimbursement Process: Competitive Bidding has provided a consistent and clear pricing mechanism for Durable Medical Equipment (DME) and oxygen therapy services
Slide 7: Transaction Rationale: Optimal Time to Consolidate RT/DME Sector
7 Transaction Rationale: Optimal Time to Consolidate Respiratory Therapy (RT) / Durable Medical Equipment (DME) Sector » Advances in COPD and sleep therapy technology to enable more personalized and efficient care » Increased diagnosis and awareness to drive continued growth in addressable patient b
Slide 8: AeroCare CEO Steve Griggs and Executive Team
8 AeroCare CEO Steve Griggs and Executive Team ▪ Founded AeroCare in 2000 ▪ 25+ years in RT/DME sector (15 years in home infusion) ▪ Former President of RoTech Medical (pre - sale to Integrated Medical System); generated rapid growth through a combination of acquisitions and organic growth to 800 lo
Slide 9: Diverse Reimbursement Profile: Payer Mix
9 Medicare 62.2% Medicaid 5.2% Private Pay / Other 2.3% Managed Care 30.3% 2012 Medicare 58.9% Medicaid 5.0% Private Pay / Other 3.2% Managed Care 32.8% 2013 Medicare 54.2% Medicaid 5.0% Private Pay / Other 4.3% Managed Care 36.5% YTD 6/30/14 Diverse Reimbursement Profile Payer Mix Medicare accounte
Slide 10: Two Key Medical Issues with Attractive Growth Profiles: COPD and OSA
10 AeroCare is Focused on Two Key Medical Issues with Attractive Growth Profiles Chronic Obstructive Pulmonary Disease (“COPD”) Obstructive Sleep Apnea (“OSA”) #3 Chronic Disease In the U.S. 15 Million People in U.S. with COPD Clear Growth Drivers ▪ $11+ billion market in the U.S. ▪ Growing at 7%+ a
Slide 11: Competitive Bidding Program Overview
11 Competitive Bidding Program (“CBP”) Overview Round 1 and Round 1 Recompete Results ▪ 1,217 contracts awarded to 356 individual suppliers ▪ Multiple winners for each product category given CMS policy to ensure a choice of suppliers for all beneficiaries in the area ▪ Approximately 51% of the winni
Slide 12: Increased Compliance Requirements and Reimbursement Changes
12 » Qualifying Sleep Test » Doctors Order for CPAP » Well Documented Face - to - Face Visit (documenting condition requiring sleep test) » Patients Must Achieve Compliance Within 90 Days of Setup » Interpretation by Board Certified Doctor » Second Face - to - Face Visit (documenting compliance and
Slide 13: Shifting Market Dynamics
13 Shifting Market Dynamics ▪ “Mom and Pop” entities challenged as cost and complexity of business have increased – Providers need capital, management expertise, critical mass and internal growth to succeed 26 37 85 33 19 36 52 27 0 10 20 30 40 50 60 70 80 90 Charlotte Dallas Miami Orlando Round 1 O
Slide 14: Growth Strategy
14 Make selective acquisitions to expand footprint Drive organic growth by adding incremental patients to existing locations Open logical de - novo locations to support growth and take market share Continue to invest in IT infrastructure and operational efficiencies to increase operation leverage Gr
Slide 15: Organic Patient Growth Supplemented by Selective Acquisitions
15 Organic Patient Growth Supplemented by Selective Acquisitions 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Jun-14 Previous Year Patients Acquired Patients Organic Patients 722 15,436 44,263 22,336 26,181 32,509 37,608 41,663 57,800
Slide 16: Acquisition Opportunities Across the Spectrum
16 ▪ 90%+ of providers in the U.S. have <$10MM of revenue ▪ Track record of identifying/acquiring targets and integrating them in the existing AeroCare business model − Over 50 acquisitions since 2006 − Time - tested, disciplined approach to the diligence and integration process ▪ Established capaci
Slide 17: Potential to Accelerate Organic Growth Through Targeted Initiatives
17 Potential to Accelerate Organic Growth Through Targeted Initiatives Additional Products & Services to Existing Referral Sources ▪ Currently exploring numerous avenues to add products and services to sell through existing referral channels: – Leverage improving physician ordering function to deliv
Slide 18: Investments in IT Will Continue to Improve Operating Margins
18 Investments in IT Will Continue to Improve Operating Margins Billing ▪ Engaged with Brightree (leading durable and home medical equipment RCM and practice management software) ▪ Connect with physician EMR system -- transition to electronic physician communication and billing data transfer ▪ Fewer
Slide 19: Transaction Valuation
19 At Closing With Full Earnout Shares Oustanding (1) 22.009 25.597 Amount in Trust per Share $8.36 $8.36 Equity Value @ $8.36 / share $184.0 $214.0 AeroCare Debt (2) 87.2 87.2 Cash (3) (59.4) (59.4) Implied Enterprise Value $211.9 $241.9 2014E Pro Forma Adjusted EBITDA (4) $36.1 $36.1 EV / 2014E Pr
Slide 20: Current and Pro Forma Ownership
20 Ferrer Freeman & Co. 29% MTS Health Partners 9% Steve Griggs, Founder & CEO 32% Directors / Other Management 12% Other Employees 18% Public Shares 34% MergeWorth Rx Insiders 12% AeroCare Shares + Options 54% Ferrer Freeman & Co. 16% MTS Health Partners 5% Steve Griggs, Founder & CEO 17% Directors
Slide 21: Comparable Companies to AeroCare
21 Closing Price as of as % of 52- Market Enterprise Company Ticker 11/7/14 Week High Value Value DaVita HealthCare Partners Inc. DVA $74.49 98.7% $16,150.9 $24,399.7 Amedisys, Inc. AMED 24.79 109.8% 824.3 956.6 Gentiva Health Services, Inc. GTIV 19.56 98.9% 727.4 1,786.4 LHC Group, Inc. LHCG 23.64
Slide 22: Comparable Companies EBITDA Metrics
22 17.4x 12.7x 9.9x 9.6x 9.4x 9.3x 8.6x 5.9x BIOS AMED DVA ADUS GTIV LHCG AFAM AeroCare NewCo 31.2% 13.5% 13.5% 4.3% 2.8% 2.5% (1.7%) (7.5%) 20.5% 20.2% 8.7% 7.8% 6.9% 6.1% 5.0% 4.8% AeroCare DVA GTIV LHCG ADUS AFAM AMED BIOS 13.6x 10.4x 9.5x 8.8x 8.7x 8.2x 8.0x 4.4x BIOS AMED DVA AFAM GTIV ADUS LHC
Slide 23: Implied Stock Price Based on 2014E Pro Forma Adjusted EBITDA Multiple Expansion
23 $8.36 $9.40 $10.22 $11.86 $13.50 $15.14 $0.00 $2.00 $4.00 $6.00 $8.00 $10.00 $12.00 $14.00 $16.00 5.9x 6.5x 7.0x 8.0x 9.0x 10.0x (1) 2014E Pro Forma Adjusted EBITDA assumes annualized contribution from completed acquisitions as well as three (3) acquisitions (all under LOI), that are expected, al
Slide 24: Summary Historical Income Statement
24 Summary Historical Income Statement Pro Forma as Adjusted Income Statement 2012 – June 30, 2014 YTD ($ in millions) (1) The three and six months stub periods ending June 30, 2014, represent unaudited numbers (2) Adjusted EBITDA is a non - GAAP measure and consists of GAAP net income (loss) as rep
Slide 25: Pro Forma Adjusted EBITDA Reconciliation
25 Pro Forma Adjusted EBITDA Reconciliation Pro Forma as Adjusted EBITDA Reconciliation 2012 – June 30, 2014 YTD ($ in millions) (1) Adjusted EBITDA is a non - GAAP measure and consists of GAAP net income (loss) as reported and adjusts for: tax provision (benefit); intere st expense and other income
Slide 26: Unaudited Balance Sheet as of June 30, 2014
26 Assets Total Liabilities and Shareholders’ Equity Unaudited Balance Sheet as of June 30, 2014 Current Assets: Cash and Cash Equivalents $0.1 Accounts Receivable, net 25.1 Inventory 6.3 Prepaid & Other Current Assets 4.4 Total Current Assets 35.9 Property & Equipment 36.8 Intangible Assets, net 12